Clinical Trial: Moderate-dose Cyclophosphamide for Childhood Acquired Aplastic Anemia

Study Status: Withdrawn
Recruit Status: Unknown status
Study Type: Interventional




Official Title: Moderate-dose Cyclophosphamide for Childhood Acquired Aplastic Anemia

Brief Summary: Severe aplastic anemia (SAA)is characterized by the depletion of hematopoietic precursors associated with life-threatening complications. High-dose cyclophosphamide has been found to yield a complete response (CR) in adults and children with SAA.However, the optimal dosage of cyclophosphamide for patients in childhood remains unclear. So we explore the ideal dosage of cyclophosphamide for the treatment of children with SAA.